Clinical Trial Update: Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety of single and repeat treatments of DaxibotulinumtoxinA for Injection for moderate to severe glabellar lines has completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facial Line Imbalance
• Glabellar Lines

Drugs mentioned

• DaxibotulinumtoxinA for Injection (daxibotulinumtoxinA)

Snippet

Sponsor: Revance Therapeutics, Inc. | Conditions: Glabellar Frown Lines | Phase 3 | Status: COMPLETED | Results posted: 2022-07-13